HealthCare Royalty Partners is a royalty acquisition company focused on commercial or near-commercial stage biopharmaceutical products. self-described.

HealthCare Royalty Partners

HealthCare Royalty | 1,961 followers on LinkedIn. Advancing Biopharmaceutical Innovation with Creative Capital Solutions | HealthCare Royalty (&quot;HCRx&quot;) is a leading royalty acquisition company focused on commercial or near-commercial stage biopharmaceutical products. HCRx has invested $5+ billion in more than 85 biopharma products since inception and has offices in Stamford (CT), San Francisco, Boston and London.  The HCRx team consists of 33 individuals (including our Senior Advisors), including former pharmaceutical executives, scientists, physicians, bankers, research analysts and consultants.

Frank Armstrong

Chief Scientific Officer at HealthCare Royalty

Shin Kang

Chief Executive Officer at Memgen

Greg Brown

Chief Medical Officer at HealthCare Royalty

Warren Cooper

HealthCare Royalty

HealthCare Royalty and Blue Owl Announce $250M Debt Financing with TG Therapeutics https://lnkd.in/e2tjDbq7

Valinor Pharma Announces Acquisition by Grünenthal with a Total Deal Value of Approximately $250 Million

Grünenthal acquires US-company Valinor Pharma and becomes global owner of Movantik®

OPKO Health and HealthCare Royalty Enter into $250 Million Note Purchase Agreement Secured by NGENLA’s Profit Share Payments

We are thrilled to share insights from the recent roundtable discussion hosted by DNB and Back Bay Life Science Advisors. On May 7th, 2024, industry leaders Clarke Futch, Chairman and CEO of HealthCare Royalty (HCRx), and Chris Posner, President and CEO of Cara Therapeutics, engaged in a thought-provoking discussion on alternative financing in healthcare. Moderated by Jonathan Gertler of Back Bay Life Science Advisors, the forum also featured Anne Grabe, Global Head of Healthcare Banking, DNB, and Patrik Ling, Senior Analyst, DNB. This diverse group of experts delved into innovative financing strategies that are shaping the future of healthcare.

Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029

Zevra Therapeutics Refinances Existing Debt With Up To $100M In Committed Capital Under New Credit Facility

Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million https://lnkd.in/ef5Ar6EC

Thank you to everyone who joined us in the Dominican Republic at our 14th Annual Senior Advisor Board Offsite. Lots of interesting and insightful sessions in a beautiful setting.

Liquidia Corporation Announces $100 Million in New Financings https://lnkd.in/ez-rBm6z

HCRX

COM:HCRX

HealthCare Royalty Partners